Partridge SC - Search Results

1

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. Partridge SC, et al. Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4. Radiology. 2018. PMID: 30179110 Free PMC article. Clinical Trial.

2

Semi-automated analysis for MRI of breast tumors.

Partridge SC, Heumann EJ, Hylton NM. Partridge SC, et al. Stud Health Technol Inform. 1999;62:259-60. Stud Health Technol Inform. 1999. PMID: 10538368

3

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

4

Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI.

Partridge SC, McKinnon GC, Henry RG, Hylton NM. Partridge SC, et al. J Magn Reson Imaging. 2001 Oct;14(4):433-8. doi: 10.1002/jmri.1204. J Magn Reson Imaging. 2001. PMID: 11599068

5

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Partridge SC, et al. AJR Am J Roentgenol. 2002 Nov;179(5):1193-9. doi: 10.2214/ajr.179.5.1791193. AJR Am J Roentgenol. 2002. PMID: 12388497

6

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. Partridge SC, et al. AJR Am J Roentgenol. 2005 Jun;184(6):1774-81. doi: 10.2214/ajr.184.6.01841774. AJR Am J Roentgenol. 2005. PMID: 15908529

7

Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.

Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM. Klifa CS, et al. Among authors: partridge sc. J Magn Reson Imaging. 2007 Jan;25(1):82-8. doi: 10.1002/jmri.20775. J Magn Reson Imaging. 2007. PMID: 17173311

8

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. Wilmes LJ, et al. Among authors: partridge sc. Magn Reson Imaging. 2007 Apr;25(3):319-27. doi: 10.1016/j.mri.2006.09.041. Epub 2007 Feb 5. Magn Reson Imaging. 2007. PMID: 17371720

9

Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions.

Williams TC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. Williams TC, et al. Among authors: partridge sc. Radiology. 2007 Jul;244(1):94-103. doi: 10.1148/radiol.2441060634. Epub 2007 May 16. Radiology. 2007. PMID: 17507720

10

Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications.

DeMartini W, Lehman C, Partridge S. DeMartini W, et al. Acad Radiol. 2008 Apr;15(4):408-16. doi: 10.1016/j.acra.2007.11.006. Acad Radiol. 2008. PMID: 18342764 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters